同步左右
发表于 2025-3-28 16:21:01
Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer, been proven that patients with mutations in exon 2 of the . ongogene gain no benefit from treatment with the monoclonal antibodies (moAbs) against Epidermal Growth Factor Receptor (EGFR), cetuximab and panitumumab. Currently, the determination of . mutational status represents a paradigm for biomar
愤愤不平
发表于 2025-3-28 18:56:24
http://reply.papertrans.cn/83/8285/828452/828452_42.png
切碎
发表于 2025-3-29 02:15:48
http://reply.papertrans.cn/83/8285/828452/828452_43.png
Resection
发表于 2025-3-29 06:02:28
http://reply.papertrans.cn/83/8285/828452/828452_44.png
词汇
发表于 2025-3-29 08:39:12
Antibody-Drug Conjugates: Can Coupling Cytotoxicity and Specificity Overcome Therapeutic Resistanceer component provides the ADC with an antibody’s exquisite selectivity for its target antigen, which is typically a cell surface molecule with a tumor-restricted expression pattern. The latter component provides the ADC with a highly potent cytotoxic payload that can efficiently kill targeted cells